Here's How I Am Buying Hims & Hers At $37 Or Earning 4.2% Monthly Instead

Hims & Hers (NYSE:HIMS) reported robust Q2 revenue of $545 million, a 73% year-over-year increase, placing the company on track for a $2.4 billion annual run rate. The analysis posits HIMS as an undervalued growth story in telehealth, citing its rapid scaling, strong EBITDA margins, and a personalized care model that drives superior retention and recurring revenue. It further argues that market concerns regarding GLP-1 regulatory changes are overblown, positioning HIMS favorably for future weight loss drug launches and significant long-term upside despite current valuation perceptions.

Analysis

Hims & Hers (HIMS) has reported significant top-line acceleration with Q2 revenue of $545 million, a 73% year-over-year increase that establishes a $2.4 billion annual revenue run rate. The provided analysis positions the company as an undervalued hypergrowth asset in the telehealth market, citing its vertically integrated, direct-to-consumer platform as a key driver for strong EBITDA margins and high customer retention. A core pillar of the bullish thesis is the assertion that market fears surrounding potential regulatory changes for GLP-1 weight loss drugs are overstated. The company's personalized care model is presented as a competitive advantage that not only mitigates this risk but also positions HIMS to capitalize on future drug launches in the weight loss category. While the valuation is acknowledged as appearing high, it is justified within the article by the combination of rapid growth and expanding margins, suggesting substantial long-term upside potential.

Key Decisions for Investors

• Investors aligned with a high-growth strategy should consider the 73% year-over-year revenue growth and strong EBITDA margins as a potential entry point, as the article frames HIMS as a significantly undervalued opportunity.
• Closely monitor regulatory news concerning GLP-1 drugs, as the investment thesis heavily relies on the view that current market concerns are overblown and that Hims can successfully navigate this landscape.
• Given the high valuation, investors should critically assess whether the company's growth trajectory and margin expansion are sustainable, as any deceleration could pose a significant risk to the stock price.
• Consider the author's options-based strategy of targeting a $37 entry point or generating income as a method to potentially mitigate risk and enhance returns on a volatile growth stock.